Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy (NCT00942903), a non-randomized phase 1 study. The primary outcome is Patient Preference for Provox HME or Provox XtraHME.

2. Clinical Question

This question is about reported preference and feasibility, rather than a randomized estimate of the difference between two assigned treatments. The stated aim was to investigate satisfaction with and performance of Provox Xtra HME in laryngectomized patients. The questionnaire comparison may capture how participants judged several aspects of use, but the registry does not report the questionnaire items, response options, scoring method, or how a participant’s responses were converted into a preference count. Those details are not reported in the registry record.

3. Trial Design

This was a Phase 1, completed, non-randomized, unmasked, single-group device study. The registry lists enrollment as 20 and identifies Provox Xtra HME as the intervention. It describes the group as laryngectomized patients who were currently compliant, 24/7 users of a Provox HME. The condition listed is total laryngectomy. The study name and brief description frame the work as a short-term feasibility assessment after total laryngectomy.

The registry gives a start date of 2009-07 and a primary completion date of 2009-08. The sponsor is Atos Medical AB. These administrative details establish the record’s context, but do not explain how participants were recruited, how many were eligible, or how many completed follow-up. Such details are not reported in the registry record.

The primary outcome is patient preference for Provox HME or Provox XtraHME, assessed by structured questionnaire over 3 weeks. The stated questionnaire concerns several aspects of using Provox XtraHME in comparison with Provox HME. Noise at stoma occlusion is listed as a secondary outcome. The record lists 2 outcome measures, but does not give results for either measure.

Although the questionnaire asks participants to compare the devices, the study design is not a randomized, two-group comparison. The registry identifies a single group and explicitly notes that the arms are not a like-for-like control comparison. Masking is listed as none. The record does not describe a separate control group, random assignment, or a blinding procedure. It also does not report a protocol, a sample-size justification, interim analyses, or a statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Patient Preference for Provox HME or Provox XtraHME, measured over 3 weeks.

The primary endpoint is titled patient preference for Provox HME or Provox XtraHME. Its unit is patients, and the registry describes the outcome as a number based on a structured questionnaire about several aspects of using the new Provox XtraHME compared with Provox HME. The assessment timeframe is 3 weeks. The result itself is not reported in the registry record.

Preference is relevant to a feasibility study because acceptability and perceived performance can inform whether a device is practical for the people expected to use it. In this study, the stated areas of interest include stoma occlusion, speaking, breathing, appearance, compliance, and short-term pulmonary symptoms. The registry does not specify which of these aspects were included in the primary questionnaire, how they were weighted, or how an overall preference was determined. It also does not report whether participants could express no preference or how incomplete questionnaires were handled.

As a general statistical point, a count of participants expressing a preference is descriptive: it reports how many people fell into a response category. It does not, by itself, quantify the size of a difference in clinical performance or establish why participants preferred one device. Because the study is single-group and non-randomized, the endpoint should be read as participant-reported preference in this study context, not as a randomized estimate of comparative treatment effect. The registry record gives no primary endpoint result or uncertainty estimate.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Interpreting a clinical study requires separating its design, endpoint, analysis, and reporting. In this record, the design is listed as single-group, non-randomized, and unmasked. The main endpoint is a patient-preference count from a questionnaire, not a time-to-event measure or a continuous measurement. The registry does not report the endpoint results or an analysis of those results. Statistical interpretation is therefore constrained by what the record documents.

What does a single-group design imply?

In general, a single-group study observes participants in one study group rather than assigning separate groups to competing treatments. A questionnaire can still ask participants to compare a new device with one they have used before, as this registry describes. But that within-questionnaire comparison is not equivalent to randomly assigning participants to separate device groups. Random assignment is one way to reduce systematic differences between groups; it is not listed for this study.

Without a concurrent randomized control group, differences in reported experience cannot be cleanly separated from other influences, such as participants’ prior experience or expectations. This is a general limitation of non-randomized comparisons, not a finding that those influences changed this study’s results. The registry does not report enough detail to evaluate such influences in this particular study.

What does a patient count tell the reader?

A count tells how many participants were recorded in a response category when the category and result are reported. The registry defines the primary endpoint as the number of patients expressing a preference based on a structured questionnaire. It does not report the category counts, the denominator used for the endpoint, or the scoring rules. Thus, the endpoint’s general form is described, but its observed distribution cannot be interpreted from this record.

As a general explanation, a confidence interval can communicate uncertainty around an estimate. Its width depends on the information available and the statistical method used. An interval does not repair limitations in the study design or make a non-randomized comparison randomized. No confidence interval for the preference endpoint is reported in the registry record.

How should the planning assumptions be understood?

The registry’s planning assumptions describe a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of the observed effect. These are assumptions for planning illustrations; they are not reported as the study’s own design plan. The study itself is listed as single-group, so equal allocation between two arms is not a description of its design.

In general, a planning sample size estimates how many participants might be needed under specified assumptions to detect a chosen effect with a chosen probability. Such a calculation depends on the assumed effect and analysis model. A planning illustration is not an observed result, and it should not be called observed power. The registry does not report a prospective sample-size justification or the assumptions used by the investigators when planning the study.

For outcomes expressed as event counts, over-dispersion can matter when variation in counts is greater than a simple model assumes. As a general statistical concept, a model that ignores over-dispersion may describe uncertainty poorly. The registry identifies the primary endpoint as a patient count, but does not report a count model, an over-dispersion assessment, or a statistical analysis plan. It would therefore be inappropriate to claim that a particular count model or adjustment was used.

What can be inferred from the analysis record?

The registry lists 0 analyses. That means the entry does not contain a recorded outcome analysis for interpretation. It does not prove that no analysis was conducted elsewhere; analyses outside the registry record are not reported in the registry record. The record also does not state whether the analysis was intended to be descriptive, whether any hypothesis test was planned, or how questionnaire data were to be handled.

General statistical interpretation depends on knowing the analysis population, the outcome definition, the denominator, the treatment of missing observations, and the method used to quantify uncertainty. These details are not reported for the primary outcome. No result or interval should be inferred from the study’s enrollment figure or from the planning assumptions. The appropriate reading is that the registry documents the study question and design features, while leaving the primary outcome analysis unavailable.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 2 outcome measures: the primary patient-preference endpoint and Noise at Stoma Occlusion as a secondary outcome. It records 0 analyses. No statistical analysis plan, testing hierarchy, or multiplicity adjustment is reported in the registry record. As a general statistical matter, assessing several outcomes or several questionnaire dimensions can create multiple opportunities to observe an apparently notable result. Whether and how that issue was addressed in this study is not reported.

The record does not describe missing-data procedures. It does not state how incomplete questionnaires, missing visits, or participants without an endpoint response were handled. The enrollment figure alone does not establish how many participants contributed data to a particular outcome. The primary outcome’s population field is blank, and the endpoint denominator is not reported in the registry record.

Analysis populations are also not described. The record does not state whether analyses were based on all enrolled participants, participants who completed follow-up, or another defined group. It would be inappropriate to assume a particular population or to treat enrollment as the denominator for every result. These gaps matter because missing observations and analysis-population choices can affect both the estimate and its uncertainty. Since outcome results and analysis details are not reported, the registry entry does not permit an assessment of their impact.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry’s safety entry lists the Provox XtraHME group with 20 participants at risk for serious adverse events and 0 affected. It also lists 20 at risk for other adverse events and 0 affected. These figures describe the counts recorded in the safety entry. They should not be interpreted as proof that no unwanted experiences occurred outside the categories captured by that entry.

The registry does not list serious adverse event terms, and it does not provide descriptions of other events. The death count is not reported in the registry record. The entry also does not explain the event-collection procedures, duration of safety follow-up, or how an event was attributed to the device. Those details limit interpretation of the zero affected counts.

As a general principle, a zero recorded count means that no affected participants were entered for that particular category in the reported safety data. It does not demonstrate that the risk is absent, nor does it establish a comprehensive safety profile. Here, the study is described as short-term, and the primary endpoint timeframe is 3 weeks, but the registry does not give a separate safety follow-up description. The safety figures should therefore be read narrowly as the posted counts, without extending them to unreported events or longer-term experience.

12. What the Result Does, and Does Not, Mean

The record identifies a focused feasibility question: patient preference for Provox XtraHME compared with Provox HME, assessed by structured questionnaire over 3 weeks. It also describes interest in satisfaction and device performance across practical aspects of use after total laryngectomy. This makes the study’s question relevant to understanding reported user experience in the described group of current, compliant Provox HME users.

The record does not report the preference result. It therefore cannot establish from the registry entry which device participants favored, how many expressed a preference, or how consistent responses were. It also does not report the secondary outcome result for Noise at Stoma Occlusion. The study’s enrollment figure is not a substitute for those missing outcome data.

The design further limits the kinds of conclusions available. A single-group, non-randomized study does not provide the same basis for causal comparison as a randomized study with separate treatment groups. In this case, the questionnaire compares perceptions of devices, but the registry explicitly indicates that there was no like-for-like control comparison. The record does not report a blinded assessment or a statistical comparison capable of resolving that limitation.

As a general point, feasibility and acceptability findings can inform questions about whether a device is usable and worth studying further, but they do not by themselves establish comparative clinical benefit. This study’s brief description mentions pulmonary symptoms and several aspects of device performance as areas considered; the record does not provide results for those aspects. No conclusion about clinical effectiveness or absence of effectiveness can be drawn from missing outcome results.

The safety entry reports zero affected participants in its serious and other adverse event categories, with 20 listed at risk for each. Those counts do not replace detailed reporting of event types and follow-up. Overall, the registry documents the study’s aims and broad design, but the unreported outcome results and analysis details prevent a quantitative judgment of preference, precision, or comparative performance.

13. Why This Trial Matters Statistically

Statistically, this trial is a useful example of the difference between a comparison in a research question and a comparative trial design. Participants were asked about preference for Provox HME or Provox XtraHME, but the study is listed as a single-group, non-randomized study. Reading the endpoint title without attending to the design could lead to an unjustified impression that the devices were compared through randomized treatment groups.

The record also illustrates why an endpoint definition is not the same as an endpoint result. It identifies a patient count derived from a structured questionnaire and gives a 3 weeks timeframe, but does not report the count, its denominator, or an uncertainty estimate. Without those elements, readers cannot assess the magnitude or precision of any preference pattern. The same issue applies to the secondary outcome, Noise at Stoma Occlusion.

Another statistical lesson concerns the distinction between planning and inference. The record gives assumptions for sample-size planning illustrations, including equal allocation between two arms, while describing the actual study as single-group. A planning assumption does not describe the implemented design, and a planning calculation is not observed power. The registry does not report a prospective sample-size justification or an analysis plan.

Finally, the entry shows the importance of transparent reporting about missing data, analysis populations, and safety follow-up. These details are not reported in the registry record. Their absence does not establish that the study lacked procedures; it means that readers cannot evaluate those procedures from this entry. For biostatisticians and clinical researchers, distinguishing documented details from unreported methods is essential to avoid overstating what a feasibility study can establish.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpretation is that the registry record does not report the primary preference result. It gives the outcome definition and timeframe, but not the response counts, denominator, or uncertainty. The secondary outcome is named, but its result is also not reported. As a result, neither the direction nor the precision of the posted outcome findings can be assessed from the record.

The design is single-group, non-randomized, and unmasked. The registry notes that the arms are not a like-for-like control comparison. The preference questionnaire compares the devices in participants’ reports, but does not provide randomized assignment to separate device groups. This limits causal interpretation and makes it important not to treat the preference question as a controlled estimate of comparative performance.

Further details needed to understand the measurements are not reported: the questionnaire’s response options and scoring, how a preference was defined, whether participants could report no preference, and how incomplete responses were handled. The registry also does not report the analysis population, missing-data methods, statistical analysis plan, sample-size justification, or interim analyses. The blank population field for the primary outcome adds uncertainty about the precise population intended for that endpoint.

The safety entry gives counts but does not report event terms, a death count, or the safety follow-up procedures. The study is described as short-term, but the record does not separately explain the period over which adverse events were collected. These limitations are specific to the available registry information; they should not be mistaken for evidence that procedures or analyses did not exist outside the record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy — NCT00942903.
• Registry record last updated 2010-10-22; status last verified 2010-10.
• Results first posted 2010-08-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00942903 is a completed Phase 1, non-randomized, unmasked, single-group device study sponsored by Atos Medical AB. It lists total laryngectomy as the condition, Provox Xtra HME as the intervention, and enrollment of 20. The registry gives a start date of 2009-07 and a primary completion date of 2009-08.

The primary outcome is patient preference for Provox HME or Provox XtraHME, based on a structured questionnaire over 3 weeks. Noise at Stoma Occlusion is listed as a secondary outcome. The registry lists 2 outcome measures and 0 analyses, but does not report outcome results, an analysis plan, or a sample-size justification.

The safety entry records 0 affected for serious adverse events and 0 affected for other adverse events, with 20 at risk for each category. Event details and the death count are not reported in the registry record. The study’s single-group design and missing outcome results limit assessment of comparative preference and precision.